Tumor Biology

, Volume 35, Issue 3, pp 2253–2257 | Cite as

RETRACTED ARTICLE: CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: A meta-analysis

  • Zheng Ma
  • Wei Guo
  • Taiqian Gong
  • Hui-Jun Niu
  • Ru-Wen Wang
  • Yao-Guang Jiang
Research Article


Previous studies proposed that CYP1A2 rs762551 polymorphism might be associated with risk of lung cancer by influencing the function of CYP1A2. However, previous studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer reported inconsistent findings. We performed a meta-analysis of the published case–control studies to assess the association between CYP1A2 rs762551 polymorphism and risk of lung cancer. PubMed and Embase were searched to identify relevant studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer, and seven studies with a total of 3,320 subjects were finally included into the meta-analysis. The pooled odds ratio (OR) and 95 % confidence interval (95%CI) was calculated to evaluate the association. Meta-analysis of total studies showed that CYP1A2 rs762551 polymorphism contributed to risk of lung cancer under all four genetic models (C versus A: OR = 1.26, 95%CI 1.13 to 1.40, P < 0.001; CC versus AA: OR = 1.61, 95%CI 1.28 to 2.04, P < 0.001; CC versus AA/AC: OR = 1.52, 95%CI 1.11 to 2.09, P = 0.009; CC/AC versus AA: OR = 1.28, 95%CI 1.10 to 1.48, P = 0.001). Subgroup analysis based on ethnicity further suggested that CYP1A2 rs762551 polymorphism was associated with risk of lung cancer in Caucasians. These results from the meta-analysis suggest that CYP1A2 rs762551 polymorphism contributes to risk of lung cancer.


CYP1A2 Lung cancer Meta-analysis Polymorphism 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Marshall AL, Christiani DC. Genetic susceptibility to lung cancer–light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.CrossRefPubMedGoogle Scholar
  5. 5.
    Oyama T, Uramoto H, Kagawa N, Yoshimatsu T, Osaki T, Nakanishi R, et al. Cytochrome p450 in non-small cell lung cancer related to exogenous chemical metabolism. Front Biosci (Schol Ed). 2012;4:1539–46.CrossRefGoogle Scholar
  6. 6.
    Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Lung cancer susceptibility: are we on our way to identifying a high-risk group? Future Oncol. 2007;3:617–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Tan XL, Spivack SD. Dietary chemoprevention strategies for induction of phase ii xenobiotic-metabolizing enzymes in lung carcinogenesis: a review. Lung Cancer. 2009;65:129–37.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nebert DW, Dalton TP. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Nishikawa A, Mori Y, Lee IS, Tanaka T, Hirose M. Cigarette smoking, metabolic activation and carcinogenesis. Curr Drug Metab. 2004;5:363–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the cyp1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279:23847–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes p450 (cyp) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007;28:1287–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, et al. Nat2 and cyp1a2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev. 2007;8:103–8.PubMedGoogle Scholar
  14. 14.
    B'Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. Cyp1a2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 2009;84:779–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, et al. Polymorphism in cytochrome p450 1a2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 2010;8:351–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Gervasini G, Ghotbi R, Aklillu E, San Jose C, Cabanillas A, Kishikawa J, et al. Haplotypes in the 5'-untranslated region of the cyp1a2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen. 2013;54:124–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  19. 19.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  20. 20.
    Aldrich MC, Selvin S, Hansen HM, Barcellos LF, Wrensch MR, Sison JD, et al. Cyp1a1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res. 2009;69:2340–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pavanello S, Fedeli U, Mastrangelo G, Rota F, Overvad K, Raaschou-Nielsen O, et al. Role of cyp1a2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet. 2012;205:278–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhao Y, Chen ZX, Rewuti A, Ma YS, Wang XF, Xia Q, et al. Quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk. PLoS One. 2013;8:e71481.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tian Z, Li YL, Zhao L, Zhang CL. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case–control studies. Gene. 2013;524:168–74.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Zheng Ma
    • 1
  • Wei Guo
    • 1
  • Taiqian Gong
    • 1
  • Hui-Jun Niu
    • 1
  • Ru-Wen Wang
    • 1
  • Yao-Guang Jiang
    • 1
  1. 1.Department of General Thoracic Surgery, Daping Hospital and Institute of Surgery Researchthe Third Millitary Medical UniversityYuzhong DistricPeople’s Republic of China

Personalised recommendations